Factors affecting medication discontinuation in patients with overactive bladder symptoms
Eun-Jung Shim, Eun-Hee Yoo, Young-Mi Kim, Donguk Kim
Obstet Gynecol Sci. 2015;58(6):507-513.   Published online 2015 Nov 16     DOI: https://doi.org/10.5468/ogs.2015.58.6.507
Citations to this article as recorded by Crossref logo
Personalized approach to pharmacotherapy of overactive bladder
Igor V. Kuzmin
Urology reports (St. - Petersburg).2023; 13(3): 267.     CrossRef
The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study
Sheng-Mou Hsiao, Ting-Chen Chang, Ho-Hsiung Lin
Maturitas.2019; 126: 11.     CrossRef
Is it possible to cure the symptoms of the overactive bladder in women?
Jan Krhut, Alois Martan, Roman Zachoval, Tomas Hanus, Lukas Horcicka, Kamil Svabík, Peter Zvara
International Urology and Nephrology.2018; 50(3): 433.     CrossRef
Comparative Persistence, Switch Rates, and Predictors for Discontinuation of Antimuscarinics for Overactive Bladder
Hao-Wei Chen, Yu-Chen Chen, Wen-Jeng Wu, Ching-Chia Li, Yu-Han Chang, Jiun-Hung Geng, Jung-Tsung Shen, Mai-Yu Jang, Kai-Fu Yang, Yung-Shun Juan
Urological Science.2018; 29(5): 223.     CrossRef
VAISTŲ, VARTOJAMŲ DIRGLIOSIOS ŠLAPIMO PŪSLĖS SINDROMO GYDYMUI, EFEKTYVUMO PALYGINIMAS
Vita Kvekšaitė, Ieva Vasilavičiūtė, Monika Zinkevičiūtė, Povilas Aniulis, Rosita Aniulienė
Sveikatos mokslai.2017; 27(3): 27.     CrossRef